ICER releases draft evidence report on treatment for advanced retinitis pigmentosa

6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on treatment for acute pain

5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...

Read more →

ICER announces new annual launch price and access report for 2025

22 January 2025 - New report will highlight opportunities to improve affordability and access, and demonstrate the importance of having ...

Read more →

ICER to assess treatments for spinal muscular atrophy

6 January 2025 - Report will be subject of Midwest CEPAC meeting in August 2025; draft scoping document open to ...

Read more →

ICER publishes fourth annual assessment of barriers to fair access within US commercial insurance prescription drug coverage

19 December 2024 - Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater ...

Read more →

ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease

16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...

Read more →

ICER announces most significant drug price hikes unsupported by new clinical evidence in US

12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...

Read more →

ICER releases draft evidence report on treatment for acute pain

9 December 2024 - Public comment period now open until 13 January 2025; requests to make oral comment during public ...

Read more →

ICER to assess treatment for secondary progressive multiple sclerosis

19 November 2024 - Report will be subject of CTAF meeting in June 2025; draft scoping document open to public ...

Read more →

ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease

31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...

Read more →

ICER publishes final evidence report on treatments for transthyretin amyloid cardiomyopathy

21 October 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...

Read more →

The ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations

18 September 2024 - Report to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding price ...

Read more →

ICER to assess treatment for retinitis pigmentosa

17 September 2024 - Report will be subject of New England CEPAC meeting in April 2025; draft scoping document open ...

Read more →

ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease

12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy

5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...

Read more →